海圣医疗（920166.BJ）：麻醉监护医疗器械小巨人，麻醉监护精准化矩阵驱动成长

Investment Rating - The report does not explicitly state an investment rating for the company. Core Insights - Haisheng Medical is recognized as a national-level specialized and innovative "little giant" in the field of anesthesia and monitoring medical devices, with a comprehensive product offering and strong market presence in China [3][18]. - The company has a solid growth trajectory, with revenue expected to reach 304 million yuan in 2024, a slight decrease of 0.70% year-on-year, but showing positive growth in the first three quarters of 2025 with a revenue increase of 19.89% [3][12]. - The company has a robust technology matrix with 63 patents, including 13 invention patents, and has undertaken numerous significant technology projects at various governmental levels [3][18]. Company Overview - Haisheng Medical specializes in anesthesia and monitoring medical devices, serving major clinical departments such as anesthesia, ICU, and emergency [3][15]. - The company has established a strong brand and marketing network, with products used in over 600 top-tier hospitals, including prestigious institutions like Peking Union Medical College Hospital [5][12]. - The revenue composition for 2024 indicates that anesthesia products account for 52.60%, monitoring products for 36.59%, and surgical and nursing products for 10.47% [30][33]. Financial Performance - In 2024, the company is projected to achieve a gross margin of 52.09% and a net margin of 23.35% [12][30]. - The net profit attributable to the parent company for 2024 is expected to be approximately 70.92 million yuan, reflecting a year-on-year decline of 9.12% [12][30]. - The company’s R&D expenses for 2024 are estimated at 16.16 million yuan, representing 5.32% of revenue, with a year-on-year growth of 21.67% in the first three quarters of 2025 [5][12]. Industry Analysis - The medical device market in China is rapidly growing, with the market size expected to increase from 440.3 billion yuan in 2017 to 1.1544 trillion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 14.76% [4][18]. - The low-value medical consumables market is projected to reach 185.2 billion yuan in 2024, with a year-on-year growth of 19.49% [4][30]. - The global medical device industry is also on an upward trend, with the market size expected to grow from 479.36 billion USD in 2023 to 637.96 billion USD by 2028 [4][18]. Competitive Position - Haisheng Medical's performance in terms of revenue growth is superior compared to its peers, with the company leading in revenue CAGR among comparable companies from 2022 to 2024 [12][14]. - The company has established a strong competitive edge through its proprietary technologies and extensive patent portfolio, which includes critical innovations in blood pressure sensors and bioelectrical signal acquisition [5][12].